SI0817637T1 - Sinergistične kombinacije zidovudina, 1592U89 in 3TC - Google Patents

Sinergistične kombinacije zidovudina, 1592U89 in 3TC

Info

Publication number
SI0817637T1
SI0817637T1 SI9630494T SI9630494T SI0817637T1 SI 0817637 T1 SI0817637 T1 SI 0817637T1 SI 9630494 T SI9630494 T SI 9630494T SI 9630494 T SI9630494 T SI 9630494T SI 0817637 T1 SI0817637 T1 SI 0817637T1
Authority
SI
Slovenia
Prior art keywords
zidovudine
synergistic combinations
synergistic
combinations
Prior art date
Application number
SI9630494T
Other languages
English (en)
Inventor
David Walter Barry
Clair Martha Heider Glaxo Wellcome Inc. St.
Original Assignee
The Wellcome Foundation Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26306774&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SI0817637(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB9506490.3A external-priority patent/GB9506490D0/en
Priority claimed from GBGB9506489.5A external-priority patent/GB9506489D0/en
Application filed by The Wellcome Foundation Limited filed Critical The Wellcome Foundation Limited
Publication of SI0817637T1 publication Critical patent/SI0817637T1/sl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Cephalosporin Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Orthopedics, Nursing, And Contraception (AREA)
SI9630494T 1995-03-30 1996-03-28 Sinergistične kombinacije zidovudina, 1592U89 in 3TC SI0817637T1 (sl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GBGB9506490.3A GB9506490D0 (en) 1995-03-30 1995-03-30 Antiviral combinations
GBGB9506489.5A GB9506489D0 (en) 1995-03-30 1995-03-30 Antiviral combinations
EP96911953A EP0817637B1 (en) 1995-03-30 1996-03-28 Synergistic combinations of zidovudine, 1592u89 and 3tc
PCT/EP1996/001352 WO1996030025A1 (en) 1995-03-30 1996-03-28 Synergistic combinations of zidovudine, 1592u89 and 3tc or ftc

Publications (1)

Publication Number Publication Date
SI0817637T1 true SI0817637T1 (sl) 2002-10-31

Family

ID=26306774

Family Applications (1)

Application Number Title Priority Date Filing Date
SI9630494T SI0817637T1 (sl) 1995-03-30 1996-03-28 Sinergistične kombinacije zidovudina, 1592U89 in 3TC

Country Status (36)

Country Link
US (1) US6417191B1 (sl)
EP (1) EP0817637B1 (sl)
JP (1) JP2954357B2 (sl)
KR (1) KR100542536B1 (sl)
CN (1) CN1103593C (sl)
AP (1) AP652A (sl)
AT (1) ATE220551T1 (sl)
AU (1) AU715213B2 (sl)
BR (3) BR9607851B1 (sl)
CA (1) CA2216634C (sl)
CZ (1) CZ295940B6 (sl)
DE (3) DE122005000029I1 (sl)
DK (1) DK0817637T3 (sl)
EA (1) EA000626B3 (sl)
EE (1) EE04047B1 (sl)
ES (1) ES2179193T3 (sl)
FR (1) FR05C0022I2 (sl)
GE (1) GEP20022647B (sl)
HK (1) HK1009401A1 (sl)
HU (1) HU224010B1 (sl)
IL (1) IL117727A (sl)
LU (1) LU91171I2 (sl)
MX (1) MX9707316A (sl)
MY (1) MY115461A (sl)
NL (1) NL300195I2 (sl)
NO (2) NO313787B1 (sl)
NZ (1) NZ306419A (sl)
OA (1) OA10616A (sl)
PL (1) PL187085B1 (sl)
PT (1) PT817637E (sl)
RO (1) RO117995B1 (sl)
SI (1) SI0817637T1 (sl)
SK (1) SK283825B6 (sl)
TR (1) TR199701074T1 (sl)
UA (1) UA60293C2 (sl)
WO (1) WO1996030025A1 (sl)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR9709939A (pt) 1996-06-25 1999-08-10 Glaxo Group Ltd Combinação formulação farmacêutica processo de tratamento de uma infecção por hiv em um animal infectado usos de éster tetraidro-3-furanila do ácido 3s[3r*(1r*,2s*)]-[-3-[[4-amino-fenil)sulfonil](2-metilprop ril)-amino]-2-hidroxi-1-fenilmetil)propil]-carbâmico de zidovudina e de (2r,cis)-4-amino-1-(2-hidroximetil-1,3-oxatiolan-5-il)-(1h)-pirimidin-2-ona e pacote para paciente
US6113920A (en) * 1996-10-31 2000-09-05 Glaxo Wellcome Inc. Pharmaceutical compositions
TW536403B (en) * 1997-03-24 2003-06-11 Glaxo Group Ltd An ethanol and ethylenediaminetetraacetic acid free pharmaceutical composition comprising lamivudine and exhibiting antimicrobial preservative efficacy
AU769660B2 (en) * 1997-05-17 2004-01-29 Glaxo Group Limited Carbocyclic nucleoside hemisulfate and its use in treating viral infections
GB9709945D0 (en) * 1997-05-17 1997-07-09 Glaxo Group Ltd A novel salt
BR9809127A (pt) * 1997-05-17 2000-08-01 Glaxo Group Ltd Combinação, formulação farmacêutica, processo para o tratamento de uma infecção por hiv em um animal infectado, uso de (-) -(1s,4r)-4-[2-amino-6-(ciclopropil amino)-9h-purin-9-il)-2-ciclopenteno-1-metanol, e, pacote de paciente
GB9809213D0 (en) * 1998-04-29 1998-07-01 Glaxo Group Ltd Pharmaceutical compositions
US6875773B1 (en) 1998-05-29 2005-04-05 Ben M. Dunn Combination therapy for treatment of FIV infection
WO1999060988A2 (en) * 1998-05-29 1999-12-02 University Of Florida Combination therapy for treatment of fiv infection
GB9820417D0 (en) * 1998-09-18 1998-11-11 Glaxo Group Ltd Antiviral combinations
US6432966B2 (en) 1999-10-29 2002-08-13 Smithkline Beecham Corporation Antiviral combinations
US7074417B2 (en) * 2000-10-13 2006-07-11 Advancis Pharmaceutical Corporation Multiple-delayed release anti-viral product, use and formulation thereof
AP2220A (en) * 2001-05-11 2011-03-24 Cipla Medpro Pty Ltd Pharmaceutical composition.
TW200403061A (en) * 2002-06-04 2004-03-01 Glaxo Group Ltd Pharmaceutical compositions
KR20090053867A (ko) 2003-01-14 2009-05-27 길리애드 사이언시즈, 인코포레이티드 복합 항바이러스 치료를 위한 조성물 및 방법
CA2518823A1 (en) 2003-03-24 2004-10-07 F.Hoffmann-La Roche Ag Benzyl-pyridazinons as reverse transcriptase inhibitors
NZ546873A (en) 2003-10-24 2010-09-30 Immunaid Pty Ltd Method of analysing immune system cycling to monitor and/or treat diseases characterised by the production of regulator T cells
TWI471145B (zh) 2005-06-13 2015-02-01 Bristol Myers Squibb & Gilead Sciences Llc 單一式藥學劑量型
BRPI0617720A2 (pt) 2005-10-19 2011-08-02 Hoffmann La Roche compostos inibidores de nnrt de fenil-acetamida, usos dos referidos compostos e composição farmacêutica que os contém
RU2469032C2 (ru) 2006-12-13 2012-12-10 Ф.Хоффманн-Ля Рош Аг Производные 2-(пиперидин-4-ил)-4-фенокси- или фениламинопиримидина в качестве ненуклеозидных ингибиторов обратной транскриптазы
PL2120878T3 (pl) * 2007-02-09 2015-01-30 Alphapharm Pty Ltd Postać dawkowania zawierająca dwa czynne składniki farmaceutyczne o różnych postaciach fizycznych
HUE026456T2 (en) 2009-05-27 2016-05-30 Biotempus Ltd Procedure for curing diseases
ES2969969T3 (es) 2010-01-27 2024-05-23 Viiv Healthcare Co Combinaciones de dolutegravir y lamivudina para el tratamiento de la infección por VIH
MX2016002560A (es) 2013-08-29 2016-10-26 Teva Pharma Forma de dosificacion unitaria que comprende emtricitabina, tenofovir, darunavir y ritonavir y un comprimido monolitico que comprende darunavir y ritonavir.
CA2942877A1 (en) 2014-04-08 2015-10-15 Nitzan SHAHAR Unit dosage form comprising emtricitabine, tenofovir, darunavir and ritonavir
AU2015303835B2 (en) 2014-08-12 2020-04-09 Monash University Lymph directing prodrugs
CA2997106C (en) 2015-09-08 2024-06-04 Monash University Lymph directing prodrugs
US11883497B2 (en) 2017-08-29 2024-01-30 Puretech Lyt, Inc. Lymphatic system-directing lipid prodrugs
CA3077739A1 (en) * 2017-08-29 2019-03-07 Puretech Lyt, Inc. Lymphatic system-directing lipid prodrugs
US11608345B1 (en) 2017-12-19 2023-03-21 Puretech Lyt, Inc. Lipid prodrugs of rapamycin and its analogs and uses thereof
US11304954B2 (en) 2017-12-19 2022-04-19 Puretech Lyt, Inc. Lipid prodrugs of mycophenolic acid and uses thereof
KR20220149534A (ko) 2020-02-05 2022-11-08 퓨어테크 엘와이티, 아이엔씨. 신경스테로이드의 지질 전구약물

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4724232A (en) * 1985-03-16 1988-02-09 Burroughs Wellcome Co. Treatment of human viral infections
US5047407A (en) 1989-02-08 1991-09-10 Iaf Biochem International, Inc. 2-substituted-5-substituted-1,3-oxathiolanes with antiviral properties
US5122517A (en) 1988-06-10 1992-06-16 Regents Of The University Of Minnesota Antiviral combination comprising nucleoside analogs
GB8815265D0 (en) * 1988-06-27 1988-08-03 Wellcome Found Therapeutic nucleosides
US5204466A (en) 1990-02-01 1993-04-20 Emory University Method and compositions for the synthesis of bch-189 and related compounds
GB9009861D0 (en) 1990-05-02 1990-06-27 Glaxo Group Ltd Chemical compounds
GB9104740D0 (en) * 1991-03-06 1991-04-17 Wellcome Found Antiviral nucleoside combination
CZ285232B6 (cs) 1991-05-16 1999-06-16 Glaxo Group Limited Protivirové směsi
ES2138624T3 (es) * 1992-05-13 2000-01-16 Wellcome Found Combinaciones terapeuticas.
US5723490A (en) 1992-09-08 1998-03-03 Vertex Pharmaceuticals Incorporated THF-containing sulfonamide inhibitors of aspartyl protease
GB9417249D0 (en) 1994-08-26 1994-10-19 Wellcome Found A novel salt
US5869461A (en) 1995-03-16 1999-02-09 Yale University Reducing toxicity of L-nucleosides with D-nucleosides
CZ429398A3 (cs) 1996-06-25 1999-05-12 Glaxo Group Limited Kombinace účinných látek a farmaceutický prostředek
BR9709939A (pt) 1996-06-25 1999-08-10 Glaxo Group Ltd Combinação formulação farmacêutica processo de tratamento de uma infecção por hiv em um animal infectado usos de éster tetraidro-3-furanila do ácido 3s[3r*(1r*,2s*)]-[-3-[[4-amino-fenil)sulfonil](2-metilprop ril)-amino]-2-hidroxi-1-fenilmetil)propil]-carbâmico de zidovudina e de (2r,cis)-4-amino-1-(2-hidroximetil-1,3-oxatiolan-5-il)-(1h)-pirimidin-2-ona e pacote para paciente
DE10226522A1 (de) * 2002-06-14 2003-12-24 Degussa Verwendung von Übergangsmetallkomplexen mit stickstoffhaltigen mehrzähnigen Liganden als Bleichkatalysator und Bleichmittelzusammensetzung

Also Published As

Publication number Publication date
NO313787B1 (no) 2002-12-02
CA2216634C (en) 2004-07-20
BRPI9612992B1 (pt) 2020-08-04
CN1103593C (zh) 2003-03-26
SK283825B6 (sk) 2004-02-03
WO1996030025A1 (en) 1996-10-03
DE122005000029I1 (de) 2005-10-06
BRPI9607851B8 (pt) 2019-11-05
HUP9801571A3 (en) 2001-04-28
EA199700203A1 (ru) 1998-02-26
HK1009401A1 (en) 1999-09-10
FR05C0022I1 (sl) 2005-06-10
KR19980703420A (ko) 1998-11-05
AU715213B2 (en) 2000-01-20
PL322532A1 (en) 1998-02-02
DE69622386D1 (de) 2002-08-22
MY115461A (en) 2003-06-30
CZ309097A3 (cs) 1998-05-13
IL117727A (en) 1999-11-30
FR05C0022I2 (sl) 2005-10-21
EE04047B1 (et) 2003-06-16
IL117727A0 (en) 1996-07-23
RO117995B1 (ro) 2002-12-30
JPH10511682A (ja) 1998-11-10
BR9607851A (pt) 1998-07-21
ATE220551T1 (de) 2002-08-15
NL300195I1 (nl) 2005-08-01
TR199701074T1 (xx) 1998-02-21
LU91171I2 (fr) 2005-07-04
MX9707316A (es) 1997-11-29
BR9607851B1 (pt) 2009-01-13
DE122005000029I2 (de) 2006-04-27
NZ306419A (en) 2000-01-28
PT817637E (pt) 2002-11-29
CN1185110A (zh) 1998-06-17
EE9700240A (et) 1998-04-15
NL300195I2 (nl) 2005-11-01
JP2954357B2 (ja) 1999-09-27
DE69622386T2 (de) 2003-02-13
AP652A (en) 1998-06-19
EA000626B1 (ru) 1999-12-29
CZ295940B6 (cs) 2005-12-14
EP0817637B1 (en) 2002-07-17
AP9701089A0 (en) 1997-10-31
NO2005014I2 (no) 2008-02-11
PL187085B1 (pl) 2004-05-31
OA10616A (en) 2001-03-15
CA2216634A1 (en) 1996-10-03
SK129597A3 (en) 1998-07-08
NO974510D0 (no) 1997-09-29
NO2005014I1 (no) 2005-06-06
UA60293C2 (uk) 2003-10-15
US6417191B1 (en) 2002-07-09
EP0817637A1 (en) 1998-01-14
DK0817637T3 (da) 2002-11-11
EA000626B3 (ru) 2016-04-29
HU224010B1 (hu) 2005-04-28
KR100542536B1 (ko) 2006-03-23
LU91171I9 (sl) 2018-12-28
NO974510L (no) 1997-09-29
AU5497296A (en) 1996-10-16
GEP20022647B (en) 2002-03-25
ES2179193T3 (es) 2003-01-16
HUP9801571A2 (hu) 1999-01-28

Similar Documents

Publication Publication Date Title
HUP9801571A3 (en) Synergistic combinations of zidovudine, 1592u89 and 3tc
AU5499896A (en) Hair treatment compositions
IL115470A0 (en) Therapeutic food composition
ZA966814B (en) Clear cosmetic gel composition.
ZA964733B (en) Ob protein compositions and methods
GB9523167D0 (en) Cosmetic composition
GB9511938D0 (en) Cosmetic composition
AU4266596A (en) Composition and use
GB9803642D0 (en) Hair treatment composition
AU9301998A (en) Composition and methods using galectin-1
AU4899497A (en) Human p2x purinoreceptor
AUPN499895A0 (en) Hair treatment composition
AU7470494A (en) Human oxalyl-coa decarboxylase
AU3983899A (en) Human promonocyte associated protein: prmnc
IL120904A0 (en) 1-C-perfluoroalkyl glycosides their preparation and their uses
HUP9903098A3 (en) Combination comprising vx478, zidovudine and/or 1592u89 and pharmaceutical composition containing them
AU2436095A (en) Cloning, expression, and uses of human lactoferrin
AU5713098A (en) Human rhombotin-like protein
AU6622196A (en) Composition and its use
GB9512703D0 (en) Composition and use
AU2002301117A1 (en) Murine and human cerberus-like proteins and compositions comprising them
AU2002301117A2 (en) Murine and human cerberus-like proteins and compositions comprising them
AU5439598A (en) Human glutamate-binding protein
AU1931399A (en) Human dendriac and brainiac-3
GB9524138D0 (en) Cosmetic composition